2 May 2014 EMA/454283/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report SonoVue International non-proprietary name: sulfur hexafluoride Procedure No. EMEA/H/C/000303/II/0025 Note Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union 1. Background information on the procedure 1.1. Requested Type II variation Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Bracco International B.V. submitted to the European Medicines Agency on 24 July 2013 an application for a variation. This application concerns the following medicinal product: Medicinal product: International non-proprietary Presentations: name: SonoVue sulfur hexafluoride See Annex A The following variation was requested: Variation requested Type II C.I.4 C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data The MAH proposed the update of section 4.3 of the SmPC in order to delete the contraindications for use in patients with acute coronary syndrome or clinically unstable ischaemic cardiac disease and to insert information on these patient populations into section 4.4 Special warnings and precautions for use, with editing of the wording as appropriate. The Package Leaflet was proposed to be updated accordingly. Furthermore, the MAH proposed this opportunity to bring the PI in line with the latest QRD template version 9. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet. Rapporteur: Pierre Demolis 1.2. Steps taken for the assessment Submission date: 24 July 2013 Start of procedure: 25 August 2013 Rapporteur’s preliminary assessment report 7 October 2013 circulated on: Rapporteur’s updated assessment report 21 October 2013 circulated on: Request for supplementary information and 24 October 2013 extension of timetable adopted by the CHMP on: MAH’s responses submitted to the CHMP on: 13 November 2013 Rapporteur’s assessment report on the MAH’s 29 November 2013 responses circulated on: 2nd Request for supplementary information and 18 December 2013 Assessment report EMA/84084/2014 Page 2/33 extension of timetable adopted by the CHMP on: MAH’s responses submitted to the CHMP on: 16 January 2014 Rapporteur’s preliminary assessment report on the MAH’s responses circulated on: 03 February 2014 Rapporteur’s updated assessment report on the MAH’s responses circulated on: 13 February 2014 3rd Request for supplementary information and extension of timetable adopted by the CHMP on: 20 February 2014 MAH’s responses submitted to the CHMP on: 21 March 2014 Rapporteur’s preliminary assessment report on the MAH’s responses circulated on: 11 April 2014 CHMP opinion (via written procedure) 29 April 2014 2. Scientific discussion 2.1. Introduction SonoVue is an ultrasound contrast agent (USCA). It contains sulphur hexafluoride (a gas) as microbubbles in suspension in a liquid, after made up into a solution (kit including one vial of gas and powder and one pre-filled syringe containing 5 ml of solvent). It is intravenous administered. Sonovue was centrally approved in Europe in 2001. Other USCA in European centralised procedure are Luminity (perflutren) and Optison (perflutren, authorised on 1998). SonoVue is approved in 36 countries world-wide and marketed in 25 countries world-wide. SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, which results in an improved signal to noise ratio. SonoVue should only be used in patients where study without contrast enhancement is inconclusive: - Echocardiography: SonoVue is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation. - Doppler of macrovasculature: SonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries by improving the Doppler signal to noise ratio. SonoVue increases the quality of the Doppler flow image and the duration of clinically-useful signal enhancement in portal vein assessment. - Doppler of microvasculature: SonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography, leading to more specific lesion characterisation. In May of 2004, SonoVue was temporarily suspended from the European market for the cardiac indication, based on reports of 3 cases of adverse events with fatal outcome and temporal relationship to SonoVue administered for echocardiography in patients with underlying severe cardiac disease. SonoVue remained on the market for use in extra cardiac indications. In July 2004, the Committee for Medicinal Products for Human Use (CHMP) recommended the re-instatement of the cardiac indication, but required the introduction of contraindications to avoid the use of the product in patients with recent acute coronary syndrome (ACS) or clinically unstable ischaemic cardiac disease, including: evolving or on-going Assessment report EMA/84084/2014 Page 3/33 myocardial infarction, typical angina at rest within last 7 days, significant worsening of cardiac symptoms within last 7 days coronary artery intervention or other factors suggesting clinical instability (for example, recent deterioration of electrocardiogram [ECG], laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders. Since 2004, additional information on the safety of SonoVue has become available from both clinical trials and post-marketing surveillance, with estimated exposure of over 2 million patients. Current contra-indications are: • known hypersensitivity to sulphur hexafluoride or to any of the components of SonoVue. • patients with recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or on-going myocardial infarction, typical angina at rest within last 7 days, significant worsening of cardiac symptoms within last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (for example, recent deterioration of ECG, laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders. • patients known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome. • pregnancy and lactation. In the currently submitted type II variation, the applicant is requesting the deletion in Section 4.3 of the contraindications for use in patients with acute coronary syndrome or clinically unstable ischaemic cardiac disease and the insertion of these patient populations into Section 4.4 Special warnings and precautions for use, with editing of the wording as appropriate. These changes are also reflected in revised wording for the PIL. The principle of this deletion was subjected to an EMA scientific advice on 20 September 2012. In conclusion, the CHMP recommended to the Applicant to submit a type II variation where the proposed change to the SmPC would be supported by the following: • A summary and discussion of similarities and differences in pharmaceutical composition of registered USCAs that could possibly be relevant to risk of adverse CV outcome. • All relevant (comparative) haemodynamic or other (clinical) pharmacology data that could address the question of potential underlying mechanism for CV risk. The Applicant should explore options for additional investigations in a sensitive model. • Meaningful observational/epidemiological / pharmacovigilance data that is relevant to the specific patient population at hand (in patients with recent acute coronary syndrome of clinically unstable ischaemic cardiac disease) and would enable a comparison between this agent and other similar USCARs (e.g. patient matching). It was not considered meaningful to expect that a prospectively planned comparative safety trial of feasible size will be sufficiently sensitive and informative to support a decision to remove the mentioned contraindications form the label. Assessment report EMA/84084/2014 Page 4/33 Additional revisions to Product information (SmPC/PIL) in accordance to QRD v.9 are also proposed, following consultation and agreement by EMA. Note Narrative summaries for the 3 post-marketing surveillance cases with fatal outcome and temporal relationship to SonoVue which led to the temporary suspension of the product from the European market are described below. • Case BRO-005943 (Germany, 2002) describes a 69-year-old male patient with history of anterior and posterior myocardial infarction, percutaneous transluminal coronary angiography (PTCA) and stent placement in left anterior descending coronary artery (LAD) was admitted for an angiographic follow-up, which showed 3-vessel disease (occlusion of right coronary artery, RCA, high grade restenosis in distal LAD stent, and several stenoses in left circumflex artery, LCx). A new revascularization of LAD in-stent- restenosis was performed successfully. The following day, the patient was feeling well except for an unusual restlessness and before